Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TK-042 long-term administration in children with perennial allergic rhinitis
jRCT2031240126Phase 3Active, not recruiting
- Sponsor
- Teikoku Seiyaku Co., Ltd.
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of donepezil in perennial rhinitis, sponsored by Teikoku Seiyaku Co., Ltd. Primary endpoint: Safety endpoints. Started Jul 2024; status: active, not recruiting.
02
Drugs
donepezil
03
Conditions
perennial rhinitis
Beyond the preview
Go deeper on jRCT2031240126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240126.